[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Canadian Medical and Surgical Knowledge Translation Research Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100575212","circulating-vascular-regenerative-cell-exhaustion-in-individuals-without-type-2-diabetes-who-are-of-south-asian-or-european-origins-100575212",false,"NCT06769347","Circulating Vascular Regenerative Cell Exhaustion in Individuals Without Type 2 Diabetes Who Are of South Asian or European Origins","ORIGINS-VRCE-2","Inclusion Criteria:\n\n1. Adults 18 years of age or older of South Asian origin or European origin as defined by the following: i. South Asian defined as any individual who identifies as Anglo-Indian, Bangladeshi, Bengali, Bhutanese, Goan, Gujarati, Indian, Jatt, Kashmiri, Maharashtrian, Malayali, Nepali, Pakistani, Punjabi, Sindhi, Sinhalese, Sri Lankan, Tamil, Telugu, or other South Asian origins. ii. European Origin defined as any individual who identifies as from western Europe, northern Europe, southern Europe, eastern Europe or other European origins.\n2. Willing and able to provide written informed consent and comply with study requirements\n3. Must fulfill the following exclusion criteria:\n\nExclusion Criteria:\n\n1. No previous diagnosis of type 2 diabetes\n2. Any previous CV events such as:\n\n   1. Prior myocardial infarction\n   2. Coronary revascularization\n   3. Coronary artery disease, peripheral artery disease, cerebrovascular disease\n3. Any life-threatening disease expected to result in death within the next 2 years\n4. Any malignancy not considered cured (except basal cell carcinoma of the skin). A subject is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening\n5. Known severe liver disease (e.g. Non-alcoholic fatty liver disease, chronic liver disease, liver cirrhosis, etc.)\n6. White blood cell count ≥ 15 x 10\\^9\u002FL\n7. Active infectious disease requiring antibiotic or anti-viral agents\n8. Known acquired immunodeficiency syndrome such as HIV\n9. On oral steroid therapy (e.g. prednisone) or other immunosuppressive agents (e.g. methotrexate)\n10. Treated autoimmune disorder",true,"ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","ORIGINS-VRCE-2 is an observational study aimed to assess how blood vessel forming stem cells from individuals without diabetes or a history of cardiovascular disease differ between individuals of South Asian and European ethnicities. The overarching objective of the study is to investigate whether differential vessel reparative stem cell populations and characteristics may underlie the elevated cardiovascular risk observed among South Asian individuals compared to individuals of European origins.",[25],"Cardiovascular Diseases Risk",[27,28,29],"Progenitor Cells","Cardiometabolic Risk","Ethnic Origins","RECRUITING","2025-11-28",{"date":33,"type":34},"2025-12-02","ACTUAL",{"date":36,"type":34},"2025-01-30",{"date":38,"type":21},"2029-01",{"name":40,"class":41},"Canadian Medical and Surgical Knowledge Translation Research Group","OTHER",5,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100564243","vascular-regenerative-cell-exhaustion-in-adults-with-peripheral-artery-disease-pad-vrce-100564243","NCT06626646","Vascular Regenerative Cell Exhaustion in Adults with Peripheral Artery Disease (PAD-VRCE)","Vascular Regenerative Cell Exhaustion in Adults with Peripheral Artery Disease","PAD-VRCE","Inclusion Criteria:\n\n1. Adults ≥18 and ≤80 years of age who meet either of the following criteria:\n\n   1. Clinically significant\u002Fsymptomatic PAD (defined as symptomatic claudication with and an ankle brachial index of less than 0.85).\n   2. No history of PAD.\n2. Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Unable or unwilling to provide written informed consent or to provide a peripheral blood sample.\n2. Any life-threatening disease expected to result in death within two years.\n3. Any malignancy not considered cured (except basal cell carcinoma of the skin). An individual is considered cured if there has been no evidence of cancer recurrence for the five years prior to screening.\n4. Uncontrolled hypertension.\n5. New York Heart Association Class IV heart failure.\n6. Active liver disease or liver dysfunction.\n7. Active kidney disease or kidney dysfunction.\n8. History of hemorrhagic stroke or other major bleeding disorder.\n9. White blood cell count of ≥15x10\\^9\u002FL.\n10. Active infectious disease requiring systemic antibiotic or anti-viral agents.\n11. Known acquired immunodeficiency syndrome, such as Human Immunodeficiency Virus.\n12. On oral steroid therapy (e.g. prednisone or other corticosteroids) or other immunosuppressive agents (e.g. methotrexate).\n13. Treated autoimmune disorders","80 Years",{"count":53,"type":21},40,"PAD-VRCE is an observational, cross-sectional, two arm study aimed at determining if the presence of peripheral artery disease (PAD) can influence the number of circulating regenerative cells in blood. From peripheral blood samples, circulating progenitor cell content will be assessed via flow cytometry and compared between individuals with PAD and individuals without PAD. Ultimately, this study plans to evaluate the relationship between PAD, vascular regenerative cell exhaustion and overall cardiovascular health.",[56,57,58,59],"Peripheral Vascular Diseases","Cardiovascular Disease","Type 2 Diabetes","Peripheral Artery Disease",[61,62,63],"Progenitor cells","Cardiovascular disease","Peripheral artery disease","2024-10-02",{"date":66,"type":34},"2024-10-04",{"date":68,"type":21},"2024-10",{"date":70,"type":21},"2025-07",{"name":40,"class":41},2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100524412","functional-investigation-of-endothelial-function-and-regenerative-cell-exhaustion-100524412","NCT06108388","Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion","Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion in Type 2 Diabetes","FIERCE","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Willing to provide written informed consent.\n* Documented history of T2D\n* No documented history of diabetes\n\nExclusion Criteria:\n\n* Unable or unwilling to provide written informed consent or provide a peripheral blood sample.\n* Any life-threatening disease expected to result in death within two years of consent.\n* Any malignancy not considered cured (except basal cell carcinoma of the skin). An individual is considered cured if there has been no evidence of cancer recurrence for the five years prior to screening.\n* Known severe liver disease.\n* White blood cell count ≥15 x 10\\^9\u002FL.\n* Active infectious disease requiring systemic antibiotic or anti-viral agents.\n* Known acquired immunodeficiency syndrome such as HIV.\n* Treated autoimmune disorders (e.g. T1D and LADA).\n* On oral steroid therapy (e.g. prednisone or other corticosteroids) or other immunosuppressive agents (e.g. methotrexate).",{"count":82,"type":21},90,"FIERCE is an observational cross-sectional study. Approximately 90 individuals living with type 2 diabetes (T2D) and\u002For individuals living without diabetes will be randomized (2:1).\n\nThe primary objective of this trial is to determine if there are differences in the content and function of circulating vascular regenerative (VR) progenitor cell subsets isolated from individuals living with T2D versus individuals not living with T2D. The main question this study aims to answer is: Does T2D compromise or enhance VR cell functionality?\n\nEach participant will be asked to provide a single blood sample. Blood samples will be processed to enumerate the number of vessel-repairing cells and determine the functionality of the different subtypes of vessel-repairing cells.",[85],"Diabetes Mellitus, Type 2",[58,87,88,89,90,91,92,93,94],"Vascular regeneration","Hematopoietic progenitor cells","Functionality","EndoPAT","Endothelial dysfunction","scRNA-seq","Colony formation assay","Secretome analyses","NOT_YET_RECRUITING","2023-11-09",{"date":98,"type":34},"2023-11-13",{"date":100,"type":21},"2023-11",{"date":102,"type":21},"2026-06",{"name":40,"class":41},1,""]